Sea bass & sea bream
Sea bass immunity to parasitic disease could lead to new treatments
No effective licensed therapies exist against amyloodiniosis, a disease of fish species caused by Amyloodinium ocellatum (AO) ectoparasites. However, new research has shown that European sea bass (ESB) can develop specific immunity to the disease, which could in turn lead to the development of vaccines.
Advanced diagnostic approaches for fish disease are welcome, but sometimes simpler is better
With technologies for molecular diagnosis of fish disease increasingly available, sometimes simpler approaches that have great diagnostic power are being ignored.
Safety and welfare concerns drive shift to licensed anesthetic in Mediterranean aquaculture
Improving standards on Mediterranean fish farms is driving interest in Tricaine PHARMAQ — the only authorized fish anesthetic product.
Vaccines boost Greece’s seabass and seabream aquaculture — but challenges remain
Aquaculture in Greece has endured some ups and downs since its establishment in the 1980s, from the Greek financial crisis to the Covid-19 pandemic.
Vaccine ‘work in progress’ in major aquaculture markets, Part 1: Sea bass
European sea bass aquaculture is centered on the Mediterranean basin, and there are a number of notable pathogens which can cause high mortality on production sites through direct and indirect effects.
Why fish vaccines are increasingly coming in smaller doses
An interview with Dr Bjørn Brudeseth, PhD, PHARMAQ
- « Previous
- 1
- 2
- 3
- Next »